The first decade of the 20th century witnessed a surge in the incidence of infections due to
several highly antimicrobial-resistant bacteria in hospitals worldwide. Acinetobacter …

Carbapenem-resistant Acinetobacter baumannii pose a significant threat to hospitalized
patients, as therapeutic options are scarse. Alarmingly, rates of carbapenem-resistance in A …

Amid the recent attention focused on the growing impact of methicillin-resistant
Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa infections, the …

Acinetobacter baumannii is an opportunistic nosocomial pathogen and one of the six most
important multidrug resistant microorganisms in hospitals worldwide. This human pathogen …

Our experience with managing an outbreak of MDR A baumannii in a medical intensive care
unit (ICU) prompted an evidence-based review of the literature, which resulted in few …

Multidrug-resistant Acinetobacter baumannii is recognized to be among the most difficult
antimicrobial-resistant gram-negative bacilli to control and treat. Increasing antimicrobial …

Acinetobacter species are widespread environmental, nonfermentative, aerobic, gram-
negative coccobacilli. Most infections due to this organism are opportunistic in nature and …

Acinetobacter baumannii (named in honor of the American bacteriologists Paul and Linda
Baumann) is a Gram-negative, multidrug-resistant (MDR) pathogen that causes nosocomial …

The optimal treatment for multidrug-resistant A. baumannii nosocomial infections has not
been established. Carbapenems are the mainstay of treatment in susceptible isolates …

Acinetobacter baumannii infections have become increasingly common among critically-ill
patients in intensive care units (ICUs) worldwide. A. baumannii clinical isolates are …